The largest holder of West Pharmaceutical Services stock is Vanguard Capital Management LLC, with 4.6 million shares (6.55% of the company), worth about $1.57 billion as of September 25, 2026. The 10 largest holders together own 43.1%.
In Q2 2026, 861 institutional holdings reports listed shares worth $25.40 billion.
Insiders reported 48 transactions in the last two years: 3 sales worth $1.35 million and no purchases. The newest one on file is from May 12, 2026 (Campbell Shane Alden, Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through May 12, 2026.

2026Q2
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Vanguard Capital Management LLC | 4.6 million | 6.55% | $1.6B |
| BlackRock Advisors LLC | 4.5 million | 6.46% | $1.6B |
| Vanguard Portfolio Management LLC | 4.0 million | 5.71% | $1.4B |
| Fidelity Management & Research Co. LLC | 3.6 million | 5.08% | $1.2B |
| State Street Corporation | 3.3 million | 4.76% | $1.1B |
| Artisan Partners Holdings LP | 2.4 million | 3.43% | $823.0M |
| BNY Mellon Investment Adviser, Inc. | 2.1 million | 2.96% | $711.0M |
| Generation Investment Management LLP | 2.0 million | 2.88% | $692.0M |
| Geode Capital Management LLC | 1.9 million | 2.70% | $649.0M |
| T. Rowe Price Investment Management, Inc. | 1.8 million | 2.56% | $616.0M |
As of September 25, 2026.
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 861 | – | $25.4B |
| Q1 2026 | 776 | 71.1 million | $17.8B |
| Q4 2025 | 835 | 70.6 million | $19.3B |
| Q3 2025 | 790 | 69.1 million | $18.1B |
| Q2 2025 | 762 | 70.9 million | $15.5B |
| Q1 2025 | 749 | 69.9 million | $15.6B |
| Q4 2024 | 783 | 69.9 million | $22.9B |
| Q3 2024 | 774 | 69.7 million | $20.8B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Campbell Shane Alden | May 12, 2026 | Officer | -- | – |
| Lockhart Stephen H | May 4, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Keller Deborah L | May 4, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Joseph Molly E. | May 4, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Feehery William F. | May 4, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Michels Douglas A | May 4, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Pucci Paolo | May 4, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Buthman Mark A | May 4, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Friel Robert F | May 4, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Haugen Janet Brutschea | May 4, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Lai-Goldman Myla P | May 4, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Winters Chad | Apr 27, 2026 | Officer | Sale at price 300.67 per share. | $269,399 |
Newest 12 of 48 insider transactions in the last two years.
Vanguard Capital Management LLC, with 6.55% of the company (as of September 25, 2026). Next: BlackRock Advisors LLC (6.46%) and Vanguard Portfolio Management LLC (5.71%).
861 institutional holdings reports listed West Pharmaceutical Services shares in Q2 2026 worth $25.40 billion.
In the last two years insiders reported 3 sales and no purchases (48 transactions in all); the newest on file is from May 12, 2026.